First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Background Approved systemic treatments for malignant pleural mesothelioma (MPM) have
been limited to chemotherapy regimens that have moderate survival benefit with poor …
been limited to chemotherapy regimens that have moderate survival benefit with poor …
[HTML][HTML] Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for …
…, I Buvat, C Castaigne, A Scherpereel… - Journal of Thoracic …, 2008 - Elsevier
Hypothesis The 2-[ 18 F]-fluoro-2-deoxy-d-glucose positron emission tomography is an
imaging tool for assessing clinical tumor, node, metastasis in non-small cell lung cancer (NSCLC)…
imaging tool for assessing clinical tumor, node, metastasis in non-small cell lung cancer (NSCLC)…
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international …
…, P De Marchi, C Martin, M Pérol, A Scherpereel… - The Lancet …, 2021 - thelancet.com
Background First-line nivolumab plus ipilimumab has shown improved overall survival in
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate whether …
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate whether …
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label …
…, F Morin, C Creveuil, JJ Parienti, A Scherpereel - The Lancet, 2016 - thelancet.com
Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …
[PDF][PDF] Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in …
F Barlesi, A Scherpereel, A Rittmeyer… - Journal of Clinical …, 2013 - researchgate.net
Purpose Maintenance therapy is associated with improved survival in patients with non–small-cell
lung cancer (NSCLC), but few studies have compared active agents in this setting. …
lung cancer (NSCLC), but few studies have compared active agents in this setting. …
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non …
A Scherpereel, J Mazieres, L Greillier… - The Lancet …, 2019 - thelancet.com
Background There is no recommended therapy for malignant pleural mesothelioma that has
progressed after first-line pemetrexed and platinum-based chemotherapy. Disease control …
progressed after first-line pemetrexed and platinum-based chemotherapy. Disease control …
Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors
…, CH Marquette, T Perez, A Scherpereel… - Annals of internal …, 2006 - acpjournals.org
Background: Diagnosis of pulmonary embolism (PE) is difficult in patients with chronic
obstructive pulmonary disease (COPD) and exacerbation. Objective: To evaluate PE in patients …
obstructive pulmonary disease (COPD) and exacerbation. Objective: To evaluate PE in patients …
Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide …
…, AS Mansfield, T Mok, A Scherpereel… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE: IMpower133 (ClinicalTrials.gov identifier: NCT02763579 ), a randomized,
double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-…
double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-…
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind …
M Maio, A Scherpereel, L Calabrò, J Aerts… - The Lancet …, 2017 - thelancet.com
Background New therapeutic strategies for malignant mesothelioma are urgently needed. In
the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated …
the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated …
Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment
BD Grigoriu, A Scherpereel, P Devos, B Chahine… - Clinical Cancer …, 2007 - AACR
Purpose: Malignant mesothelioma is a highly aggressive tumor and is often diagnosed too
late for a curative treatment. We compared diagnostic and prognostic values of mesothelin …
late for a curative treatment. We compared diagnostic and prognostic values of mesothelin …